Influence of serum epidermal growth factor on mechanical ventilation and survival in patients with acute respiratory distress syndrome

Therapy

Volumn 2, Issue 3, 2005, Pages 393-398

  Salari, Pooneh ^a   Mojtahedzadeh, Mojtaba ^a   Abdollahi, Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute respiratory distress syndrome; Epidermal growth factor; Mortality; Outcome

Indexed keywords

EPIDERMAL GROWTH FACTOR; OXYGEN; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTERIAL OXYGEN TENSION; ARTICLE; ARTIFICIAL VENTILATION; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; FEMALE; HOSPITAL ADMISSION; HUMAN; HYPOTHESIS; LUNG LAVAGE; MALE; MORTALITY; OUTCOMES RESEARCH; POSITIVE END EXPIRATORY PRESSURE; PREDICTION; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SURVIVAL RATE; TIME;

EID: 20344383728     PISSN: 14750708     EISSN: None     Source Type: Journal    
DOI: 10.1586/14750708.2.3.393     Document Type: Article

References (59)

1. Murray JF, Matthay MA, Luce JM et al. An expanded definition of the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 138, 720-723 (1988).
2. MacNaughton PD, Evans TW. Management of adult respiratory distress syndrome. Lancet 339, 469-472 (1992).
3. Weiland JE, Davis WB, Holter JF et al. Lung neutrophils in the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 133, 218-225 (1986).
4. Pratt PC, Vollmer RT, Shelburne JD, and Crapo JD. Pulmonary morphology in a multihospital collaborative extracorporeal membrane oxygenation project. Am. J. Pathol. 95, 191-214 (1979).
5. Zapol MW, Trelstad RL, Coffe JW et al. Pulmonary fibrosis in severe acute respiratory failure. Am. Rev. Respir. Dis. 119, 547-554 (1979).
6. Martin C, Papazian L, Payan MJ et al. Pulmonary fibrosis correlates with outcome in adult respiratory distress syndrome: a study in mechanically ventilated patients. Chest 107, 196-200 (1995).
7. Hill JD, Ratliff JL, Parrott JCW et al. Pulmonary pathology in acute respiratory insufficiency: Lung biopsy as a diagnostic tool. J. Thorac. Cardiovasc. Surg. 71, 64-71 (1976).
8. Antonelli M, Raponi G, Lenti L et al. Leukotrienes and α-tumor necrosis factor levels in the bronchoalveolar lavage fluid of patient at risk for the adult respiratory distress syndrome. Minerva Anestesiol. 60, 419-426 (1994).
9. Miller EJ, Cohen AB, Nagao S et al. Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality. Am. Rev. Respir. Dis. 146, 427-432 (1992).
10. Chollet-Martin S, Montravers P, Gibert C et al. High levels of interleukin-8 in the blood and alveolar spaces of patients with pneumonia and adult respiratory distress syndrome. Infect. Immun. 61, 4553-4559 (1993).
11. Meduri GU, Kohler G, Headley S et al. Inflammatory cytokines in the BAL of patients with ARDS: Persistent elevation over time predicts poor outcome. Chest 108, 1303-1314 (1995).
12. Goodman RB, Strieter RM, Martin DP et al. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 154, 602-611 (1996).
13. Tomashefski JF Jr. Pulmonary pathology of acute respiratory distress syndrome. Clin. Chest Med. 21, 435-466 (2000).
14. Bouros D, Alexandrakis MG, Antoniou KM et al. The clinical significance of serum and bronchoalveolar lavage inflammatory cytokines in patients at risk for acute respiratory distress. BMC Pulmonary Med. 4(1), 6 (2004).
15. Desai TJ, Cardoso WV. Growth factors in lung development and disease: friends or foe? Respire Res. 3(1), 2 (2002).
16. Geiser T. Mechanisms of alveolar epithelial repair in acute lung injury. Swiss Med. Wkly 133, 586-590 (2003).
17. Geiser T, Jarreau PH, Atabai K, Matthay A. Interleukine-1β augments in vitro alveolar epithelial repair. Am. J. Physiol. Lung Cell. Mol. Physiol. 279, L1184-L1190 (2000).
18. Marquardt H, Hunkapiller MW, Hood LE, Todaro GJ. Rat transforming growth factor Type 1: structure and relation to epidermal growth factor. Science 223, 1079-1082 (1984).
19. Todaro GJ, Fryling C, De Larco JE. Transforming growth factors produced by certain human tumor cells: polypeptides that interact with epidermal growth factor receptors. Proc. Natl Acad. Sci. USA 77, 5258-5262 (1980).
20. Silver MH, Murray JC, Pratt RM. Epidermal growth factor stimulates type-v collagen sythesis in cultured routine palatal shelves. Differentiation 27, 205-208 (1984).
21. Turley EA, Hollenberg MD, Pratt RM. Effect of epidermal growth factor/urogastrone on glycosaminoglycane synthesis and accumulation in vitro in the developing mouse palate. Differentiation 28, 279-285 (1985).
22. Edwards DR, Murphy G, Reynolds JJ et al. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J. 6, 1899-1904 (1987).
23. r 95,000 Type IV collagenase /gelatinase and interstitial fibroblast type collagenase by rat mucosal keratinocytes. J. Biol. Chem. 268, 19143-19151 (1993).
24. Leco KJ, Khokha R, Pavloff N et al. Tissue inhibitor of metalloproteinase-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J. Biol. Chem. 269, 9352-9360 (1994).
25. Malarkkan N, Snook NJ, Lumb AB. New aspects of ventilation in acute lung injury. Anaesthesia 58, 647-667 (2003).
26. Salari P, Mojtahedzadeh M, Najafi A et al. Comparison of the effect of aminophylline and low PEEP versus high PEEP on EGF concentration in critically ill patients with ALI/ARDS. J. Clin. Pharm. Therap. 30, 139-144 (2005).
27. Bernard G, Artigas A, Brigham KL et al. The American-European Consensus Conference on ARDS. definitions, mechanisms, relevant outcomes, and clinical trial co-ordination. Am. J. Respir. Crit. Care Med. 149, 818-824 (1994).
28. Canonico AE, Brigham KL. The Lung: Scientific Foundations Lippincot Raven, PA, USA 2476-2477 (1997).
29. Knaus WA, Draper EA, Wagner DP et al. APACHE: a severity of disease classification system. Crit care Med. 13, 818-829 (1985).
30. Lemaire F. The prognosis of ARDS: Appropriate optimism? Intensive Care Med. 22, 371-373 (1996).
31. Ware LB, Matthay MA. The acute repiratory distress syndrome. N. Eng. J. Med. 4, 1334-49 (2000).
32. Baughman RP, Gunther KL, Rashkin MC et al. Changes in the inflammatory response of the lung during acute respiratory distress syndrome: Prognostic indicators. Am. J. Respir. Crit. Care Med. 154, 76-81 (1996).
33. Connelly KG, Repine JE. Markers for predicting the development of acute respiratory distress syndrome. Ann. Rev Med. 48, 429-445 (1997).
34. Meduri GU, Headley S, Kohler G et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Chest 107, 1062-1073 (1995).
35. Headley AS, Tolley E, Meduri GU. Infections and inflammatory response in acute respiratory distress syndrome Chest 111(5), 1306-1321 (1997).
36. Kovacs EJ, DiPietro LA. Fibrogenic cytokines and connective tissue production. FASEB J. 8, 854-861 (1994).
37. Marshall RP, Bellingan G, Webb S et al. Fibroproliferation occurs early in the acute respiratory syndrome and impacts on outcome. Am. J. Respir. Crit. Care Med. 162 1783-1788 (2000).
38. Rom WN, Basset P, Fells GA et al. Alveolar machrophages release an insulin-like growth Factor I type molecule. J Clin Invest 82, 1685-1693 (1988).
39. Madtes DK, Rubenfeld G, Klima LD et al. Elevating transforming growth factor-α levels in bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 158, 424-430 (1998).
40. Chesnutt AN, Kheradmand F, Folkesson HG et al. Soluble transforming growth factor-α is present in the pulmonary oedema fluid of patients with acute lung injury. Chest 111, 652-656 (1997).
41. Agouridakis P, Kyriakou D, Alexandrakis MG et al. The predictive role of serum and bronchoalveolar lavage cytokines and adhesion molecules for acute respiratory distress syndrome development and outcome. Respir Res. 3(1):25 (2002).
42. Agouridakis P, Kyriakou D, Alexandrakis MG et al. Association between increased levels of IL-2 and IL-5 and outcome in patients with early acute respiratory distress syndrome. Eur J Clin Invest 32, 862-867 (2002).
43. Ruairi JF, Lichtenberger F, McKeegan CB et al. The acute respiratory distress syndrome: A role for transforming growth factor-β1. Am J Respir Cell Mol Biol 28, 499-503 (2003).
44. Amat M, Miquel B, Jordi M et al. Evolution of leukotrien B4, peptide leukotriens and interleukin-8 plasma concentrations in patients at risk of acute respiratory distress syndrome: Mortality prognostic study. Crit Care Med. 28, 57-62 (2000).
45. Clark JG, Milberg JA, Steinberg KP et al. Type III procollagen peptide in the adult respiratory distress syndrome: Association of increased peptide level in bronchoalveolar lavage fluid with increased risk for death. Ann Intern Med. 122, 17-23 (1995).
46. Meduri GU, Tolley EA, Chinn A et al. A procollagen Type I and III aminoterminal propeptide levels during acute respiratory distress syndrome in response to methylprednisolone treatment. Am. J. Respir. Crit. Care Med. 158, 1432-1441 (1998).
47. Miller EJ, Cohen AB, Nagao S et al. Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality. Am. Rev. Respir. Dis. 146, 427-432 (1992).
48. Donnelly SC, Strieter RM, Kunkel SL et al. Interleukin-8 and development of adult respiratory distress syndrome in at risk patients groups. Lancet 341, 643-647 (1993).
49. Dreyfuss D, Basset G, Soler P et al. Intermittent positive pressure hyperventilation with high inflation pressures produces pulmonary microvascular injury in rats. Am. Rev. Respir. Dis. 132, 880-884 (1985).
50. Dreyfuss D, Soler P, Basset G et al. High inflation pressure pulmonary edema: Respective effects of high airway pressure, high tidal volume, and positive end expiratory pressure. Am. Rev. Respir. Dis. 137, 1159-1164 (1988).
51. Ranieri VM, Suter PM, Tortorella C et al. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: A randomized controlled trial. JAMA 282, 54-61 (1999).
52. Ferguson ND, Frutos-Vivar F, Esteban A et al. Airway pressures, tidal volume and mortality in patients with acute respiratory distress syndrome. Crit care Med. 33, 21-30 (2005).
53. Gattinoni L, DAndrea L, Pelosi P et al. Regional effects and mechanism of positive end expiratory pressurein early adult respiratory distress syndrome. JAMA 269, 2122-2127 (1993).
54. Dreyfuss D, Saumon G. Role of tidal volume, FRC, and end inspiratory volume in the development of pulmonary edema following mechanical ventilation. Am. Rev. Respir. Dis. 148, 1194-1203 (1993).
55. West JB, Mathieu-Costello O. Stress failure of pulmonary capillaries: Role in lung and heart disease. Lancet 340, 762-767 (1992).
56. Muscedere JG, Mullen JB, Gan K, Slutsky AS. Tidal ventilation at low airway pressures can augment lung injury. Am. J. Respir. Crit. Care Med. 149, 1327-1334 (1994).
57. Hudson LD. Protective ventilation for patients with acute respiratory distress syndrome. N. Engl. J. Med. 338, 385-386 (1998).
58. Verghese GM, McCormick-Shannon K, Mason RJ et al. Hepatocyte growth factor and keratinocyte growth factor in pulmonary edema fluid of patients with acute lung injury. Am. J. Respir. Crit. Care Med. 158, 386-394 (1998).
59. Stern JB, Fierobe L, Paugam C et al. Keratinocyte growth factor and hepatocyte growth factor in bronchoalveolar lavage fluid in acute respiratory distress syndrome. Crit care Med. 28, 2326-2333 (2000).